---
title: "Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278939638.md"
description: "On March 12, 2026, Plus Therapeutics, Inc. (Nasdaq: PSTV) shared its financial results for the fourth quarter and full year ending on December 31, 2025. Plus, a healthcare firm specializing in precision diagnostics and radiopharmaceuticals for CNS cancers, outlined recent and forthcoming business highlights."
datetime: "2026-03-12T20:16:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278939638.md)
  - [en](https://longbridge.com/en/news/278939638.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278939638.md)
---

# Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

On March 12, 2026, Plus Therapeutics, Inc. (Nasdaq: PSTV) shared its financial results for the fourth quarter and full year ending on December 31, 2025. Plus, a healthcare firm specializing in precision diagnostics and radiopharmaceuticals for CNS cancers, outlined recent and forthcoming business highlights.

### Related Stocks

- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [PSTV.US](https://longbridge.com/en/quote/PSTV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md)
- [Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham](https://longbridge.com/en/news/282904330.md)
- [BioNTech Reports Phase 1/2a Study Data For BNT323/DB-1303 In HER2-Expressing Endometrial Cancer](https://longbridge.com/en/news/282508084.md)
- [FDA issues complete response letter to Replimune’s RP1 for melanoma](https://longbridge.com/en/news/282511585.md)
- [Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform](https://longbridge.com/en/news/282587297.md)